Why Merion Road just added JHG and ACNT—and what it says about 2026 stock picking
Merion Road Capital added Janus Henderson and Ascent Industries in Q4. Find out what’s behind the picks—and why these value plays could matter in 2026.
Can Galmed Pharmaceuticals avoid delisting? Nasdaq compliance clock is ticking
Nasdaq has notified Galmed Pharmaceuticals of a share price deficiency. Find out what this means for investors and the company's future strategy.
Why LyondellBasell’s $1.5bn EBITDA plan could reshape how the petrochemicals sector defines profitability
LyondellBasell targets $1.5B in recurring EBITDA by 2028 as it pivots toward capital discipline, cost efficiency, and structural margin recovery. Read the full analysis.
What George Botic’s PCAOB appointment says about SEC enforcement in 2026
The SEC appoints George Botic as PCAOB chair. Find out how this move could reshape audit inspections, cross-border enforcement, and AI-era oversight.
What do Peloton’s mass layoffs really signal about the future of at-home fitness?
Peloton is laying off 11% of its workforce in a major reset. Find out what this move means for its survival, investor sentiment, and fitness industry shifts.
From $100bn to equity stake: What Nvidia’s pivot in OpenAI’s funding round really signals for AI’s future
Explore how Nvidia’s revised investment in OpenAI’s funding round reshapes AI infrastructure strategy and market dynamics. Read the analysis now.
With margins stabilizing, AZZ Inc. just made a $100m move that investors can’t ignore
AZZ Inc. has authorized a new $100M share repurchase program. Find out what this means for its capital strategy and where it could head next.
Is Hong Kong still a financial hub? Federated Hermes thinks $2.7bn says yes
Federated Hermes plans Hong Kong expansion and targets $2.7B in mandates for 2026. Find out why this move could reshape the firm’s Asia strategy today.
Rithm Acquisition Corp.’s compliance crunch: Can the SPAC survive a delisting threat?
Rithm Acquisition Corp. risks delisting after NYSE non-compliance notice. Find out what’s next for the SPAC and what this signals for the broader market.
What’s going on at Olema Oncology? CFO + COO Hans Bishop exits suddenly
Olema Oncology CFO and COO Hans Bishop has stepped down ahead of OP-1250 trial milestones. Find out what this means for investors and pipeline strategy.